CritiTech Moves Into New North Lawrence, Kansas, Headquarters
09/16/2013
“We are very excited about our new home,” said Matthew McClorey, CritiTech’s COO. “Due to the growth the company has experienced over the past year, we needed more space to accommodate our growing laboratory and forthcoming API manufacturing operations.”
CritiTech’s focus at its new facility will be using its proprietary fine-particle drug development and production technology to help its customers develop new, improved and differentiated human and animal pharmaceutical drugs. CritiTech expects to use the manufacturing space in its facility to produce API for clients as they advance their drugs from the research and development stage through Phase I and Phase II clinical trials.
“Our target is to be operating in a FDA-regulated, cGMP compliant environment later this year,” said Gary Clapp, vice president of Technical Operations. “The new facility has been very helpful in showcasing our resources and expertise in fine particle drug development. The new laboratories, analytical equipment and manufacturing capabilities have impressed potential clients, customers and strategic partners. They can now see CritiTech has completed the transition from an R&D company to one that is ready to work hands on with them to develop and produce fine particle drugs that have a competitive advantage and distinct value proposition.”
Article Discussion
Most Read
-
-
2018 Leading Metro Locations: Pacific and Mountain Metros Dominate the List
Q2 2018
-
33rd Annual Corporate Survey & the 15th Annual Consultants Survey
Q1 2019
-
2018 Top States for Doing Business: Georgia Ranks #1 Fifth Year in a Row
Q3 2018
-
Made in America: An Outlook for Manufacturing in the U.S.
Location USA 2018
-
A Changing Food Manufacturing Industry
2017 Food Processing
-
Opportunity Zones Can Uplift Communities and Investors Alike
Q2 2019